Alginates are linear anionic polysaccharides present in the cell walls of brown seaweeds. They are composed of blocks of 1,4-linked β-D-mannuronic acid (M) and α-L-guluronic acid (G) arranged in M, G, and mixed MG blocks. Alginates are assumed to be indigestible in humans, but bacteria isolated from fecal samples can utilize alginates. Moreover, genomes of some human gut microbiome–associated bacteria encode putative alginase-degrading enzymes. Here, we genome-mined a poly-G-degrading endolyase that further degrades unsaturated oligosaccharides with a degree of polymerization of 2–7 from alginates and alginate oligosaccharides have applications in the food and pharmaceutical industries (11).

PL6 initially releases unsaturated oligosaccharides of a degree of polymerization of 2–7 from alginates and alginate oligosaccharides have applications in the food and pharmaceutical industries (11).

Alginates are linear anionic polysaccharides present in brown algae consisting of 1,4-linked β-D-mannuronic acid (M) and α-L-guluronic acid (G) arranged in M, G, and mixed MG blocks. Alginase was assumed to be indigestible in humans, but bacteria isolated from fecal samples can utilize alginates. Moreover, genomes of some human gut microbiome–associated bacteria encode putative alginase-degrading enzymes. Here, we genome-mined a poly-G-degrading endolyase that further degrades unsaturated oligosaccharides with a degree of polymerization of 2–7 from alginates and alginate oligosaccharides have applications in the food and pharmaceutical industries (11).

PL6 was solved by X-ray crystallography to 1.3 Å resolution, revealing a single-domain, monomeric parallel β-helix containing a 10–step asparagine ladder characteristic of alginase-converting parallel β-helix enzymes. Substitutions of the conserved catalytic site residues Lys-249, Arg-270, and His-271 resulted in activity loss. However, imidazole restored the activity of BcelPL6-H271N to 2.5% that of the native enzyme. Molecular docking oriented tetra-mannuronic acid for syn attack correlated with M specificity. Using biochemical analyses, we found that BcelPL6 initially releases unsaturated oligosaccharides of a degree of polymerization of 2–7 from alginates and polyMG, which were further degraded to di- and trisaccharides. Unlike other PL6 members, BcelPL6 had low activity on polyMG and none on polyG. Surprisingly, polyG increased BcelPL6 activity on alginates 7-fold. LC–electrospray ionization–MS quantification of products and lack of activity on NaBH₄-reduced octa-mannuronic acid indicated that BcelPL6 is an endolysase that further degrades the oligosaccharide products with an intact reducing end. We anticipate that our results advance predictions of the specificity and mode of action of PL6 enzymes.
PLs are categorized in 37 families in the CAZy database (www.cazy.org)\(^3\), 10 of which (PL5–7, -14, -15, -17, -18, -32, -34, and -36) contain alginate lyases (18, 19). Alginate lyases break the O–C4 bond to uronic acid residues through a β-elimination reaction that leads to formation of the 4,5-unsaturated sugar 4-deoxy-L-erythro-hex-4-enopyranosyluronic acid (denoted as Δ) at the nonreducing end of the released product. Alginate lyases are either endo-acting (2), initially releasing oligosaccharides that can undergo further degradation, typically to di- and trisaccharides (14, 20), or exo-acting producing the unsaturated monosaccharide Δ (Fig. 1B) (21, 22). A PL6 family enzyme has yet to be characterized from the gut niche. PL6 is multispecific and can be divided into three subfamilies (19), PL6_1 of endo- and exo-acting alginate or dermatan sulfate–specific enzymes, and PL6_2 and PL6_3, which are reported to contain only polyMG endolyses (20). Most characterized alginate lyases of PL6_1 have broad substrate specificity on polyMG and polyG (20, 23, 24), but a few, e.g. Patl3640 and Pedša0631 from Pseudomonas atlantica and Pseudobacter saltans respectively, are strictly polyG-specific (20).

With regard to three-dimensional structures, alginate lyases adopt several different folds: β-jelly roll; (α/α)\(_m\), toroid; and parallel β-helix, and some are multimodular (21, 22, 25). PL6 displays a right-handed parallel β-helix fold similar to several other polysaccharide lyase families (21, 22, 25). The first PL6 crystal structure was determined for the single domain chondroitin B lyase from Pedobacter heparrinus DSM 2366 (PDB code 1OFL) that degrades dermatan sulfate (26). Recently, structures also became available for two marine bacterial alginate lyases, namely the polyG-specific homodimeric, two-domain exoylase AlyGC from Paraglaciecola chatamensis S18K6T (PDB code 5GKQ) that produces Δ, and the mono- meric, single-domain endolysy AlyF from Vibrio splendidus OU2 (PDB code 5Z9T), releasing unsaturated trisaccharides from alginate and polyG (27, 28). PL6 thus encompasses various types of specificity toward alginates as well as for dermatan sulfate, an O-sulfated glycosaminoglycan of alternating 1,3-β-D-galactosamine and 1,4 α-L-iduronic acid (20, 21). PL6 is proposed to have conserved lysine and arginine residues acting as catalytic residues. This is opposed to alginate lyases of other PL families in which tyrosine and histidine are identified as catalytic residues. This reflects that target substrate variation probably correlates with subtle changes in the active-site structure in PL6 (26–29). Therefore, sequence-based prediction of PL6 specificities is currently not reliable.

**Specificity and mode of action**

BcelPL6 catalyzed the release of products with unsaturated nonreducing ends (Fig. 1B) from alginate (Fig. 2A) and polyM (Fig. 2B). The reactions followed Michaelis-Menten kinetics, and \( k_{cat} \) was 8-fold higher for polyM (43.4 ± 1.6 s\(^{-1}\)) than alginate (\( k_{cat} = 5.4 \pm 0.15 \) s\(^{-1}\)), whereas \( K_m \) was 3-fold lower for alginate (0.59 ± 0.04 mg ml\(^{-1}\)) than polyM (\( K_m = 1.96 \pm 0.18 \) mg ml\(^{-1}\)) (Table 1). Activity was barely detected toward polyG (Fig. 2C; Table 1; Fig. S2A) and polyMG (Table 1; Fig. S2B) even at high concentrations (6 μM) of BcelPL6, and the observed very low rates of degradation of 0–2.0 mg ml\(^{-1}\) polyG or polyMG did not follow Michaelis-Menten kinetics (Table 1). Trace of product formation from polyG possibly stems from the 3% M being found in the used polyG candidate substrate. Moreover, BcelPL6 did not degrade acetylated polyM that mimics bacterial alginate (Table 1 and Fig. S2C) (8).

LC-ESI-MS analysis showed that BcelPL6 initially released unsaturated oligosaccharides of DP2–7 from alginate with DP4 and DP6 transiently increasing in abundance and DP2 being the predominant end product (Fig. 3A; Table S1). Monosaccharide products were not observed. Molecular masses of released unsaturated oligosaccharides of DP2–7 were confirmed using MALDI-TOF MS (Fig. S3) and quantified by LC-ESI-MS. BcelPL6 released di- and trisaccharides from polyM (Fig. S4).
with pentasaccharides dominating initially (Fig. S4; Table S1). Size-exclusion chromatography (SEC) on Superdex 200 that separates linear dextrans of 1–100 kDa showed increasing amounts of unsaturated breakdown products of alginate (\(\bar{M}_n = 40\) kDa) as a broad asymmetric peak containing oligosaccharides (Fig. 3B). Thus unsaturated oligosaccharides are the primary products in agreement with the LC-ESI-MS analysis (Fig. 3A). As no unsaturated higher molecular weight products were observed (Fig. 3B), the mode of action of BcelPL6 can be described as a specific attack on M blocks in alginate followed by further degradation of the released oligosaccharides (20, 23). This is in agreement with both endo- and exo-lyases to occur in PL6_1 (20, 24, 27). Moreover, BcelPL6 seems to recognize the reducing end of the oligosaccharide substrates as it did not fur-

Figure 1. Schematics illustrating alginate block structures and general lyase mechanism of PL6 enzymes. A, 1,4-linked \(\alpha\)-L-guluronic acid block (top), 1,4-\(\beta\)-\(\delta\)-mannuronic acid and \(\alpha\)-L-guluronic acid mixed linkage block (middle), and 1,4-linked \(\beta\)-\(\delta\)-mannuronic acid block (bottom). \(n\) represents the continued polymer. B, syn-mechanism of alginate lyases with positions of catalytic Brønsted acid (pink) and base (blue) and the uronic acid group neutralizer, ++ (typically Ca\(^{2+}\); in red).

Figure 2. Kinetics and specificity of BcelPL6. Michaelis-Menten plots of alginate degraded by 100 nm BcelPL6 (A) and polyM degraded by 50 nm BcelPL6 (B). Insets in A and B show linear regression of the initial part of the progress curve (from 0.2 mg ml\(^{-1}\) (purple) to 4.2 mg ml\(^{-1}\) (black) substrate). C, progress of absorbance at 235 nm by action of 300 nm BcelPL6 on 0.2–2.2 mg ml\(^{-1}\) polyM (blue) or polyG (black).
ther degrade octa-mannuronic acid after NaBH₄ reduction (Fig. S2D).

**PolyG activation of BcelPL6**

Addition of polyG to BcelPL6 acting on alginate increased the activity up to 5-fold at 3.3 mg ml⁻¹ polyG (Fig. 4A), with $k_{cat}$ and $K_m$ both increasing about 7-fold (Fig. 4B). The polyG binding was monitored by decreased fluorescence intensity of BcelPL6 and $F_{max}$ blue-shifted by 1 and 1.5 nm using excitation wavelengths of 280 and 295 nm, respectively (Fig. 4C, insets). A $K_D$, app of $2.9 \pm 0.2$ mg ml⁻¹ polyG of 6 – 8 kDa (equivalent to 363 – 483 μm) was determined by fitting a one-site binding model to the intensity decrease (Fig. 4C). The presence of polyG did not affect $T_m$ of BcelPL6 as shown by DSC (Fig. 4D).

**Biochemical characterization**

BcelPL6 retained full activity for alginate after 5 min at 65 °C, but lost 86% activity at 70 °C (Fig. 5A) in agreement with a $T_m$ of 68.8 °C (Fig. 4D). The inactivation of BcelPL6 at 65 °C showed a half-life of 34 min (Fig. 5B). Activity toward alginate was suppressed to 50% in the presence of 350 mM NaCl and was almost completely lost in 0.95 M NaCl (Fig. 5C). Various acidic compounds and neutral sugars did not significantly change the activity, except for sodium-citrate presumably chelating the essential Ca²⁺ in BcelPL6 leading to loss of activity (Fig. 5S). The activity optimum for alginate degradation was found to be around pH 7.5 in 50 mM sodium phosphate (Fig. 5D).

**Three-dimensional structure**

BcelPL6 crystallized from 0.2 M calcium acetate, 0.1 M Tris-HCl, pH 7.0, 20% PEG 3000 in the space group P2₁, and the structure was solved at 1.3 Å resolution (Fig. 6; Table 2) with two molecules in the asymmetric unit. Both PISA analysis (33) and SEC (Fig. 6E) indicated that BcelPL6 is a monomer in solution. BcelPL6 is a right-handed parallel β-helix formed by three β-sheets similar to the other three available PL6 structures (PDB codes 1OFL, 5GKD, and 5Z9T) (Fig. 6C) (27–29). In the β-helix fold nomenclature, PB₁–3 are the parallel β-sheets, and T₁–3 are the connecting loops (34). A complete “helix turn” thus comprises PB₁–T₁–PB₂–T₂–PB₃–T₃, with PB₁ being designated to contain the active site (Fig. 6D) (35). Although the T2 loops have a distinct shape (Fig. 7A, see also below), T loops generally lack secondary structure except for a T₁ forming a two-turn α-helix loop in the C-terminal part of the β-helix (Fig. 6D). The C-terminal segment of the polypeptide (residues 432–468) adopts two three-turn α-helices parallel to the plane of β-sheets PB₃ (Fig. 6C). The N-terminal part of the β-helix has an α-helix in the plane of PB₁ (Fig. 6D), and the C-terminal part has an α-helix and a β-strand almost perpendicular to PB₃ (Fig. 6, C and D). These structural elements match β-helix features referred to as the N-terminal helix cap and C-terminal visor cap, generally needed to avoid oligomerization and amyloid formation of β-helix proteins (36). The visor cap is kept in place by a hydrogen bond from Gly-423 to an asparagine ladder that creates an extensive hydrogen bond network on the hydrophobic side of T2 loops leading to their distinct shape (Fig. 7A). The asparagine ladder in BcelPL6 contains 10 > 95% conserved residues across 1944 sequences sharing no more than 80% identity pairwise: Cys-135, Cys-169, Asn-199, Asn-234, Asn-258, Asn-280, Asn-305, Asn-350, Asn-376, and Asn-402; 7 of which (boldface) are >98% conserved (Fig. 7; Table S2).

Electron density indicated Ca²⁺ and two acetate molecules near the putative catalytic lysine and arginine residues in BcelPL6 (Fig. S6; Table S2). The Ca²⁺ is assumed to neutralize the C6 carboxylate group at subsite +1 (Fig. 6B), thus facilitating substrate binding and lowering the $pK_a$ of the C5 departing proton in the lyase reaction (27, 29). This is consistent with the loss of BcelPL6 activity after dialysis against EDTA (Fig. 6F).

**Docking of tetra-mannuronic acid (DP4M)**

Attempts to solve the structure of BcelPL6 in complex with DP3G, DP4G, DP3M, DP4M, or BcelPL6 reaction products were unsuccessful. Therefore, DP4M was docked into the active site. Using Glide (Schrödinger suite 2016-1), 12 among the 68 docked ligand conformations had a glide score $<−9$ kcal mol⁻¹, but in only one was the C5 proton on the side of the sugar ring that allows syn-elimination and points toward the catalytic residues (Fig. 6B). The carboxylic acid group of DP4M at subsite −1 aligns with acetate shown in the native BcelPL6 structure (Fig. 6B) and interacts with His-219 at subsite −1, whereas C5 carboxyl groups at subsites +2 and −2 interacted with the 98% conserved Arg-294 and Arg-216, respectively (Fig. 6B).

The putative BcelPL6 catalysts Lys-249 and Arg-270 were mutated to Ala or His and Ala or Tyr, respectively, where His and Tyr represent the pair of catalytic residues found in all other alginate lyases, but not in PL6 (21). These four BcelPL6 mutants were inactive. Moreover, the $T_m$ of K249H and R270Y decreased by 5 and 15 °C, respectively (Fig. 8, A and B), indicating an effect on the conformational stability, whereas the corresponding alanine mutants were stabilized by several degrees (Fig. 8B). The 95% conserved His-271 situated between subsites +1 and −1 appears critical for activity as BcelPL6 H271N was inactive, although it retained the $T_m$ of BcelPL6 WT (Fig. 8B). Addition of imidazole restored up to 2.5% of the WT activity (Fig. 8C), supporting that His-271 is implicated in the function.

**Alignment of BcelPL6 with the crystal structures of AlyGC (PDB 5GKD) and AlyF (PDB code 5Z9T) highlighted conserved residues important for catalytic activity and previously investigated by mutational analysis (27, 28). However, BcelPL6 differs by Arg-160 that corresponds to AlyGC Tyr-130 and Trp-172 in AlyF (Table S3) as well as two notable positions at subsites +1 and −1, where BcelPL6 has His-219 and Ser-338 corresponding to AlyGC T190 and Arg-303, respectively, both situated to
interact with substrate. Notably, His-219 binds with the docked DP4M at subsite /H11002 (Fig. 6B).

The large positively-charged active-site area in both AlyF and AlyGC did not resemble BcelPL6 (Fig. 9). Introducing positive and other side chains by mutation in BcelPL6 to mimic AlyGC (Fig. 10) did not result in activity on polyG, the substrate preferred by both AlyGC and AlyF. For polyM and alginate, BcelPL6 D153Q and Y155S had decreased $k_{\text{cat}}$ and $K_m$ values (Fig. 8A), whereas R160Y showed lower $k_{\text{cat}}$ and unaltered $K_m$ values for these two substrates. Furthermore, W184R has 6-fold reduced $k_{\text{cat}}$ on both polyM and alginate, and 4- and 15-fold reduced $K_m$ on polyM and alginate, respectively (Fig. 8).

These residues thus play a role in activity but appear not to contribute to controlling the polyM versus polyG specificity. Surprisingly, G177K, H219T, and S338R had $K_m$ values decreased by 3–12-fold on alginate, but practically unchanged on polyM compared with WT. The $k_{\text{cat}}$ was lowered by 5–10-fold on both substrates (Fig. 8A).

**Figure 3. Progress of products release by BcelPL6 from alginate.** A, quantification of reaction products (LC-ESI-MS) during 0–120 min. B, size-exclusion chromatography (Superdex 200) of products of degradation from 4 mg ml$^{-1}$ alginate by 100 nM BcelPL6. Curves (blue to brown) correspond to reaction for 0, 1, 5, 10, 20, 30, 60, 90, and 120 min prior to enzyme inactivation. Dashed line is the conductivity, which drops due to low salt in the samples and the SEC-run being complete.

**Figure 4. BcelPL6 activation by polyG.** A, initial velocity of 50 nM BcelPL6 degrading 3 mg ml$^{-1}$ alginate in the presence of 0–3.3 mg ml$^{-1}$ polyG. B, influence of polyG on $K_m$ (blue) and $V_{\text{max}}$ (black) for alginate degradation normalized to values without polyG. C, fluorescence intensity of BcelPL6 with 0–4.5 mg ml$^{-1}$ polyG and excitation at 280 nm (left) and 295 nm (right). The vertical red line on scans indicate the fluorescence maximum wavelength. D, DSC of BcelPL6 with 5 mg ml$^{-1}$ polyG (red) and without (black). Vertical red lines indicate $T_m$.  

![Image](image-url)
**Discussion**

*Becl*PL6 is the first structure-determined and thoroughly-characterized PL6 alginate lyase from HGM. In PL6, sequence-based prediction of substrate specificity is generally difficult and seems to vary with small structural differences at the active site (27). The present results on *Becl*PL6 therefore strengthen future prediction of substrate specificity and mode of action of related enzymes. An extremely low activity on polyG and polyMG distinguishes *Becl*PL6 from previously characterized PL6 alginate lyases, which were found to be polyMG (20, 23) and or polyG-specific (20, 24, 27). A polyM preference was so far seen only for PL6 from *Pseudomonas* sp. PapOS ALG-9, which also showed ~25% activity on polyG (37). Alginate lyases preferring polyM similarly to *Becl*PL6 have been identified from PL5, -7, -14, -15, -17, -18, -32, and -36 (17–19, 38–42).

Alginate endo-lyases are described to release unsaturated oligosaccharides, which are then further degraded (2). Exo-lyases by contrast release unsaturated monouronic acid (21, 22). *Becl*PL6 probably requires the reducing end for further degradation of initially produced oligosaccharides (Fig. 11), because octa-mannuronic acid was a substrate, whereas the corresponding alcohol, prepared by reduction with NaBH₄, was not degraded. Previously, some PL8 chondroitin lyases were reported to act from the substrate-reducing end (43).

### *Becl*PL6 structure

The two other PL6 alginate lyase structures, AlyGC from the marine bacterium *Paraglaciecola chatamensis* S18K6T (PDB code 5GKD) and AlyF *V. splendidus* OU2 (PDB code 5Z9T), are a solution homodimer (27) and a monomer, respectively (28). *Becl*PL6 is also monomeric (Fig. 6). The activity of polyG-specific AlyGC (27), the polyM-specific *Becl*PL6, and the chondroitin B lyase (PDB code 1OFL) (29) depends on Ca²⁺. This, however, was reported not to be the case for the polyG-specific AlyF (28).

*Becl*PL6 has a rather flat and open active site; in AlyGC the C-terminal dimerization domain partly covers the active site forming a cleft (27), and in AlyF, loops form a closed active site over the nonreducing end of the bound DP4G (28). This difference in active-site topology may explain that *Becl*PL6 releases oligosaccharides and AlyGC monosaccharides (Fig. 9). As *Becl*PL6 is a single-domain monomer, the subunit rotation between the two domains of AlyGC suggested to shape the cleft involved in catalysis (22, 27) cannot be a general feature of PL6. Also, *Becl*PL6 has a notably lower salt tolerance than the marine AlyGC, which remains 50% active in 0.5 M NaCl (27) as opposed to *Becl*PL6 that only retains 10% activity at 0.55 M NaCl, reflecting adaptation to their individual niches.

The docked DP4M interacts with *Becl*PL6 Arg-294 and Arg-216 (Fig. 6B), and the corresponding arginines in AlyGC and AlyF were shown to be important for activity (27, 28). Notably, when the C5 proton is in a position compatible with proton abstraction by the catalytic base, the direction of the orientation of DP4M in the complex was flipped compared with DP4M bound in AlyGC (PDB 5GKQ) (Fig. 9; Fig. S7). This fits well with *Becl*PL6 requiring the reducing end for degrading oligosaccha-
Figure 6. Ribbon representation of BcelPL6 (PDB 6QPS). 

A, zoom-in of active site with PL6 conserved catalytic residues Lys-249 and Arg-270 as well as the His-271, situated between subsites −1 and +1, and the neutralizing Ca^2+ (red).  

B, docked DP4M with subsites indicated. The yellow molecule is an acetate found in the crystal structure presumably from the crystallization solvent.  

C, overall structure of BcelPL6; black box indicates the active-site zoom-in in A.  

D, N- and C-terminal parts of the β-helix with the capping features and sheets (PB1–PB3) named.  

E, analytical SEC of BcelPL6 (Superdex 75). The inset is the standard curve of lysozyme, β-lactoglobulin, and BSA yielding a molecular mass of BcelPL6 of 52.3 kDa (theoretical 52.9 kDa). F, increase in absorbance at 235 nm as a function of time of 4 mg ml\(^{-1}\) alginate degradation by 100 nM BcelPL6 dialyzed against 50 mM HEPES, pH 7.3, 150 mM NaCl (solid line), or 50 mM HEPES, pH 7.3, 150 mM NaCl, 1 mM EDTA (dashed line).
Table 2

| Data collection and refinement statistics of BcePL6 |
|---------------------------------------------------|
| Resolution range | 55.4–1.29 (1.33–1.29) |
| Space group | P21 |
| a (Å) | 58.62 |
| b (Å) | 129.95 |
| c (Å) | 66.99 |
| β (°) | 113.9 |
| Wavelength (Å) | 0.873 |
| Total reflections | 1,513,764 (22,663) |
| Unique reflections | 230,084 (22,663) |
| Multiplicity | 6.6 (6.1) |
| Completeness (%) | 99.7 (96.6) |
| Mean I/σ(I) | 7.23 (1.69) |
| Wilson R-factor | 11.14 |
| R-merge | 0.123 (0.753) |
| R-meas | 0.134 (0.824) |
| R-pim | 0.052 (0.329) |
| CC(%) | 0.998 (0.553) |
| CC × | 0.999 (0.835) |
| Reflections used in refinement | 230,056 (22,261) |
| Reflections used for R-free | 11301 (1106) |
| R-work | 0.159 (0.261) |
| R-free | 0.175 (0.278) |
| CC(work) | 0.976 (0.808) |
| CC(free) | 0.970 (0.790) |
| No. of nonhydrogen atoms | 8671 |
| Macromolecules | 7389 |
| Ligands | 18 |
| Solvent | 1264 |
| Protein residues | 890 |
| Root mean square (bonds) | 0.011 |
| Root mean square (angles) | 1.09 |
| Ramachandran favored (%) | 98.08 |
| Ramachandran allowed (%) | 1.92 |
| Ramachandran outliers (%) | 0.00 |
| Rotamer outliers (%) | 0.13 |
| Clashscore | 5.79 |
| Average B-Factor | 16.81 |
| Macromolecules | 14.62 |
| Ligands | 23.27 |
| Solvent | 29.55 |
| No. of TLS groups | 12 |

*Numbers in parentheses refer to data in the highest-resolution shell.

**Structure and function of polyM-specific alginate lyase**

The high preference of BcePL6 for polyM matches with the monomeric structure and its flat active site (Fig. 9), as M-specific enzymes apply a syn-mechanism (21, 22) that requires both of the catalytic functions to be on the same side of the sugar ring (see Figs. 1 and 6, A and B). Still, PL6 enzymes with dual M and G specificity have been reported, which indicates that structure-based explanation of the specificity needs to be further developed (23, 24, 27). Conservation of His-271 at the active site and loss of activity of BcePL6 H271N suggest this residue is critical for activity (Figs. 6 and 8 and Table S2). However, the effect of mutating His-271 in the G-specific PL6 lyases AlyGC and AlyF is negligible (27, 28), and the equivalent chondroitinase B mutant retains 25% activity toward dermatan sulfate (44). Taken together, it indicates that this histidine plays a particularly important role in the depolymerization of polyM. Notably, the mannorurate epimerases AlgG and AlgE4, which also have a parallel β-helix fold, both have a conserved histidine in the active site (45, 46). This residue is proposed to act as catalytic base abstracting the C5 proton at subsite +1 as part of the epimerization mechanism with an arginine functioning as charge neutralizer (45, 46). In both of these two available epimerase structures, the distance between histidine and arginine is about the same as in BcePL6 (45, 46). There could be an evolutionary relationship between alginate epimerases and lyases, and His-271 may function as a catalytic base in the M-specific BcePL6. PROpKa (47) calculates the pKa value of His-271 to 2.0 without ligand and −0.17 in the docked complex with DP4M. Therefore, His-271 cannot become protonated at pH 7.3. Hence, His-271 is likely not active as a catalytic group, although it may still be critical for substrate recognition for polyM as supported by the loss of activity of BcePL6 H271N.

**PolyG as activator**

In the presence of polyG, Kₘ and kₑₐₑ both increased by about the same factor as for BcePL6 acting on alginate (Fig. 3B); thus, the catalytic efficiency was not affected by polyG. Assuming the reaction follows the simple mechanism shown in Reaction 1,

\[ E + S \stackrel{k_{f1}}{\longrightarrow} ES \stackrel{k_{r2}}{\longrightarrow} E + P \]

where \( k \) denotes a reaction rate then we achieve Equations 1 and 2,

\[ K_m = \frac{k_{f1} + k_{r2}}{k_{f1}} \quad (\text{Eq. 1}) \]

\[ k_{r2} = k_{cat} \quad (\text{Eq. 2}) \]

\( K_m \) and \( k_{cat} \) both increase if \( k_{r2} \) increases. If \( k_{r2} \) increases, \( K_m \) would decrease, whereas \( k_{cat} \) remains unaltered. Therefore, it may be \( k_{r2} \) that is affected by addition of polyG. One possibility is that polyG binds stronger to the active site than the products but weaker than the substrates, thus being able to expel the reaction product, which is easily displaced by substrate. This is supported by \( K_m = 0.58 \pm 0.04 \text{mg ml}^{-1} \) for alginate and \( K_{d_{app}} = 2.9 \pm 0.2 \text{mg ml}^{-1} \) for polyG binding to BcePL6. That \( k_{cat}/K_m \) is unchanged by the addition of polyG further supports that it is the later steps of the reaction that are affected.

**Asparagine ladder**

The five polysaccharide lyase families PL1, -3, -6, -9, and -16 (26, 48–51) adopt a parallel β-helix catalytic domain fold. Among these, PL1, -6, and -9 contain a so-called asparagine ladder (26, 49, 51). The 10-“step” asparagine ladder in BcePL6 ends by Gly-423 in the C-terminal visor cap, indicating its possible implication in prevention of amyloid fibril formation (36).
Sequence analysis of families PL1, PL9, and AlgG epimerases revealed that conserved asparagine ladders are only found in β-helix enzymes acting on alginate and not in pectin and pectate lyases (Fig. 7; Table S2). Asparagine ladders may confer rigidity and prevent conformational rearrangement of the secondary structure upon binding of the polyelectrolyte alginate.

In summary, recombinant BcelPL6 from B. cellulosilyticus is M-specific and produces mainly disaccharides as end products from alginate and di- and trisaccharides from polyM. BcelPL6 does not degrade polyG, polyMG, or acetylated polyM to a significant degree. The BcelPL6 crystal structure solved to 1.3 Å is monomeric similarly to AlyF and opposed to the homodimeric PL6 alginate lyase AlyGC. The more positively charged and narrow active site in AlyGC compared with BcelPL6 may explain the specificity difference. Moreover, the monomeric BcelPL6 only allows syn-elimination making it mannuronate-specific. The conserved His-271 at subsite +1 was found to be crucial for activity. The present thorough characterization of BcelPL6 improves the general insight into PL6 structure and function and will advance future identification and specificity assignment of alginate lyases from this family.

**Experimental procedures**

**Materials**

*B. cellulosilyticus* CRE21 was purchased from Deutsche Sammlung von Mikroorganismen und Zellkulturen DSM number 14838 (Germany). Brain Heart Infusion broth and LB broth
were purchased from Sigma. Alginate $M_w$ of M/G ratio = 0.6 was a kind gift of DuPont Nutrition and Health (Denmark). PolyM ($F_G = 0.0, M_w = 3$ kDa) was obtained from an epimerase-negative AlgG mutant of *Pseudomonas fluorescens* (52). PolyG $M_w = 6–8$ kDa ($F_G = 0.97$) was prepared as described previously (2); alternating polyMG ($F_G = 0.46, F_{GG} = 0.0$) of DP30 was made by epimerization of polyM in vitro using AlgE4 (53). Alginate oligomers for product identification were obtained by fractionation of alginate hydrolysates on SEC columns as described previously (2). Octa-mannuronic acid (DP8M) was reduced by NaBH₄ opening the ring structure at the reducing end without affecting the remaining residues (54, 55). Briefly, to DP8M in MQ water (4 mg ml⁻¹) was added NaBH₄ (s) 5% (w/v). Solid substances added to aqueous sub-

Figure 8. Characterization of BcelPL6 mutant enzymes. A, kinetic data of WT and mutants normalized to WT values for A: top, alginate; bottom, polyM. $k_{cat}$ (black), $K_m$ (red), and $k_{cat}/K_m$ (blue). B, melting temperature of WT and mutants determined by DSC. The black line represents WT melting temperature. C, imidazole rescue of activity of BcelPL6 H271N toward 4 mg ml⁻¹ alginate.

Figure 9. Electrostatic surface representation of PL6 alginate lyases. A, AlyF in complex with DP4G (PDB code 6ITG). B, BcelPL6 in complex with DP4M docked into the active site. C, AlyGC in complex with DP4M (PDB code 5GKQ). Figure was prepared using PyMOL 2.0 and APBS electrostatics.
stances are denoted (s) and (aq), respectively. After 1 h at ambient temperature, the mixture was kept on ice, and glacial acetic acid was added dropwise until no further gas production was observed, and pH was adjusted to 7.0 with dilute NaOH. The sample was dialyzed against two shifts of 50 mM NaCl and then against MQ water until conductivity was <2 μS, followed by freeze drying.

Bioinformatics

Lyase sequences were retrieved from the Uniprot database (56) using protein blast with 1PCL, 1RU4, and 4NK6 and BcelPL6 as queries, and clustered on a 90% identity threshold on CD-Hit(57). Iterative multiple sequence alignments were performed with Clustal Omega (58) to select the maximum number of sequences of 15–80% pairwise identity. The degree of amino acid residue conservation was assessed on the examined sequences.

Growth of B. cellulosilyticus

Isolation of genomic DNA. B. cellulosilyticus was grown overnight under anaerobic conditions (Whitley DG250 anaerobic work station) in 5 ml of Brain Heart Infusion medium supplemented with 5 μg ml⁻¹ hemin at 37 °C. Cells were harvested by centrifugation (2800 × g, 4 °C, 20 min; Eppendorf 5810 R centrifuge), and genomic DNA was isolated (59). DNA concentration was determined spectro photometrically at 260 nm.

PCR, cloning, and mutagenesis

PCR on genomic DNA was performed using Phusion High-Fidelity DNA Polymerase (New England Biolabs) with the following primers for In-Fusion cloning: 5′-CGCAGCCCGCCAGCCATATGAAAGAGTATARATATTTTCACCGAAAG-3′ and 5′-GCTCAATTGGATCCCTCACCGATTGTATCGATATGG-3′ covering the BcelPL6 gene from residue 19 to omit the signal peptide predicted by SignalP (60). The PCR product and the p28a + plasmid linearized by BamHI and NdeI (New England Biolabs) were purified by agarose gel electrophoresis and ligated using the In-Fusion cloning kit (Takara Bio) according to the manufacturer’s protocol. The resulting plasmid was verified by sequencing (GATC Biotech, Germany). This construct N-terminally extends recombinant BcelPL6 by MGSSH-HHHHHSSGLPRGSH (a His-tag and a thrombin cleavage site). The plasmid was transformed in Escherichia coli BL21. Site-directed mutagenesis was performed using a QuickChange lightning site-directed mutagenesis kit (Agilent), and the point mutation was verified by sequencing (GATC Biotech, Germany). Mutagenesis primers can be found in Table S4.

Production and purification of recombinant BcelPL6

The cryostock was cultured in LB medium at 37 °C overnight, inoculated (10 ml) in 1 L LB-KAN medium, and grown to OD₆₀₀ = 0.6–0.8 (37 °C, 160 rpm). Expression was induced by isopropyl β-D-thiogalactopyranoside added to 0.5 mM followed by incubation (22 °C, 16 h). Cells were harvested by centrifugation (5000 × g, 4 °C, 15 min) and stored at −20 °C. Pellet corresponding to 0.33 liters of culture was resuspended in 20 ml of 50 mM HEPES, pH 7.3, 150 mM NaCl, lysed (pressure cell homogenizer; Stansted Fluid Power, UK), and centrifuged (20,000 × g, 20 min). HisPur™ nickel-nitrilotriacetic acid resin (2 ml; Thermo Fisher Scientific), pre-equilibrated in 20 ml of 50 mM HEPES, pH 7.3, 150 mM NaCl, was added to the supernatant with gentle mixing (30 min). The resin was washed with 20 ml of 20 mM imidazole, 50 mM HEPES, pH 7.3, 150 mM NaCl, and the protein was eluted by 10 ml of 300 mM imidazole in the same buffer. Eluate (10 ml) was immediately gel-filtered (Hi-
load Superdex 75 26/60; GE Healthcare) in 50 mM HEPES, pH 7.3, 150 mM NaCl at a flow rate of 2 ml min$^{-1}$. Protein purity was assessed by SDS-PAGE (Fig. S1), and the concentration was determined spectrophotometrically at 280 nm using the predicted (Protparam) $\epsilon = 65,820 \text{ M}^{-1} \text{ cm}^{-1}$. The yield was typically about 30 mg liter$^{-1}$ culture. All purification steps were performed at 4 °C.

**Enzyme activity and kinetics**

Substrates (5 mg ml$^{-1}$) dissolved in 50 mM HEPES, pH 7.3, 150 mM NaCl were centrifuged prior to use. Kinetics were determined for 100 nM BcePL6 on alginate and polyMG, 50 nM on polyM, 50 nM as well as 6 $\mu$M on polyG using 0–4 mg ml$^{-1}$ substrates. Samples were mixed in a 96-well UV-star chimney well plate (In Vitro, Australia), equilibrated at 37 °C (5 min), and enzyme was added. Formation of unsaturated uronic acid products was measured spectrophotometrically at 235 nm every 10 s for 10 min at 37 °C (Bio-Tek Powerwave XS; Holm and Halby, Denmark) (16, 61) and converted to molar concentration using $\epsilon = 6150 \text{ M}^{-1} \text{ cm}^{-1}$ (62, 63). The initial part of progress curves was analyzed by linear regression (Origin 2016; Originlab), and initial rates versus substrate concentrations were fitted to the Michaelis-Menten model (64). All data points are with the standard deviation of a triplicate. Activation by 0–3.33 mg ml$^{-1}$ polyG was assayed either at 3 mg ml$^{-1}$ alginate or in kinetic assays (as above) at 0, 0.16, 0.66,
and 3.33 mg ml\(^{-1}\) polyG. PolyG was thoroughly dialyzed to remove Ca\(^{2+}\) to avoid an artifact by reconstituting eventually Ca\(^{2+}\)-depleted BcelP6. Activation and inhibition by sodium citrate sodium phosphate, sodium carbonate, maltotriose, lactose, and sodium acetate were assayed as described above at a compound concentration of 2 mg ml\(^{-1}\).

**Spectrofluorometry of polyG binding**

BcelP6 (500 nm) was emission scanned with and without polyG at 320–365 nm with excitation at 280 or 295 nm and also analyzed by measuring polyG (0–4.5 mg ml\(^{-1}\)) at 320–365 nm with excitation at 280 nm (LS-55 luminescence spectrometer; PerkinElmer Life Sciences). The \(K_{d,\text{app}}\) was obtained from the binding curve that was fitted to a standard one site-binding model as shown in Equation 3,

\[
y = y_0 + \frac{a[L]}{K_d + [L]} \tag{Eq. 3}
\]

where [L] is ligand concentration; \(y_0\) is fluorescence intensity at [L] = 0; and \(y_0 +\) is fluorescence intensity at saturation. This model assumes that \([L]_{\text{free}} \sim [L]_{\text{total}}\), which is only valid for weak interactions.

**Product analysis by size-exclusion chromatography and MS**

Mixtures (2 ml) of 4 mg ml\(^{-1}\) alginate and 100 nm BcelP6 were incubated at 37 °C and inactivated at 90 °C at 0, 1, 5, 10, 20, 30, 60, 90, and 120 min, and the reaction products were separated by SEC (Superdex 200 16/60) in 50 mM HEPES, pH 7.3, 700 mM NaCl at a flow rate of 0.5 ml min\(^{-1}\) and monitored at 235 nm. Breakdown for 20 mg ml\(^{-1}\) alginate by 100 nm BcelP6 was analyzed at 0, 2, 5, 10, 30, 60, 120, and 240 min by LC-ESI-MS. Collected samples were stored at −20 °C until quantification of oligosaccharide products by LC-ESI-MS (Amazon SL iontrap; Bruker Daltonics, Germany, coupled to UltiMate 3000 UHPLC equipped with an Ultimate R5 diode array detector (235 nm), Dionex). Samples (5 μl) in 50% ACN were injected (GlycanPac AXH-1 column, 150 × 2.1 mm; Thermo Fisher Scientific, Waltham, MA) and eluted at 0.4 ml min\(^{-1}\) at 30 °C by a three-eluent system of water (solvent A), 100 mM ammonium formate pH 5 (solvent B), and ACN (solvent C), keeping 19% A at time (in minutes) with the eluent profile: 0–10 isocratic 1% B; 10–45 linear gradient to 19% B; 45–50 linear gradient to 1% B; 50–60 isocratic 1% B. The electrospray was operated in negative mode with enhanced resolution mode and scan range 100–2000 m/z, smart parameter setting of 500 m/z, capillary voltage at 4.5 kV, end plate off-set 0.5 kV, nebulizer pressure at 3.0 bars, dry gas flow at 12.0 liters min\(^{-1}\), and dry gas temperature at 280 °C. Identification by m/z and quantification at 235 nm using \(c = 6150 \text{ m}^{-1} \text{ cm}^{-1}\) (62, 63) was done in Compass QuantAnalysis 2.2 (Bruker Daltonics, Germany) using Equation 4,

\[
c = \frac{\text{dilution} \times \text{area} \times \text{flow}}{\text{length} \times \text{ext. coeff.} \times \text{injection volume}} \tag{Eq. 4}
\]

ESI-MS results were confirmed by MALDI-TOF for 0- and 120-min reaction mixtures (buffer exchanged to 300 mM acetic acid, HiPrep desalt 26/110, GE Healthcare) spotted onto an MTP Anchor chip target with 9 mg ml\(^{-1}\) DHB matrix in 30% ACN analyzed by MALDI-TOF/TOF MS (Ultraflex II, Bruker Daltonics) in linear positive mode. Mass spectra were analyzed using Flex Analysis (Bruker Daltonics).

**Differential scanning calorimetry**

BcelP6 WT and mutants dialyzed against 50 mM Na\(_2\)HPO\(_4\)/NaH\(_2\)PO\(_4\) pH 7.3, 150 mM NaCl (3 × 100-fold dilution, 10–14 kDa cutoff, 4 h, 4 °C; Spectrum Labs, Greece) were subjected at 1 mg ml\(^{-1}\) to DSC (20–90 °C; scan rate of 1 °C min\(^{-1}\)) at constant pressure of 3 atm (NANO DSC; TA). Reversibility of unfolding was examined by scanning the sample twice. The reference cell contained dialysis buffer. A blank scan of dialysis buffer was subtracted as baseline and the data were converted to molar heat capacity using NanoAnalyze (TA).

**Analytical size-exclusion chromatography**

BcelP6 (2 ml, 10 μM) was analyzed by SEC (HiLoad Superdex 75 16/60) in 50 mM HEPES, pH 7.3, 150 mM NaCl at 4 °C (flow rate: 1 ml min\(^{-1}\)). Lysozyme (14.4 kDa), β-lactoglobulin A (36.6 kDa), and BSA (66.5 kDa) were used for calibration.

**Crystallization and X-ray diffraction**

BcelP6 dialyzed against 50 mM HEPES, pH 8.0, 50 mM NaCl (3 × 100-fold dilution, 4 h, 4 °C, 10–14 kDa cutoff) was concentrated to 20 mg ml\(^{-1}\) (10-kDa Amicon centrifugal filtration column; Merck) and used with MCGS-1 crystal screen kit (Anatrace) according to the manufacturer’s protocol. Briefly, each reservoir in four 24-well sitting drop crystallization plates (Hampton Research) was filled (500 μl) with one of the 96 different conditions, and 2 μl of protein solution was placed on the drop shelf and mixed with 2 μl of reservoir solution prior to sealing the plate (Crystal Clear Sealing tape; Hampton Research). The plates were stored 12 days at ambient temperature, and the crystals obtained (with 0.2 μl calcium acetate hydrate, 0.1 μl Tris-HCl, pH 7, 20% (w/v) PEG 3000) were flash-frozen with PEG 400 as cryoprotectant, using liquid nitrogen. Diffraction data were collected at the ESRF (ID23-2; Grenoble, France).

**Data processing, structure solution, and model building**

Diffraction images were processed automatically with Dials using the Xia2 interface and scaled with aimless (see Table 2 for details) (65–69). The structure of AlyGC (PDB code 5GKD) was used for molecular replacement with Phaser (70). First, AlyGC chain A (residues 2–443) was extracted and used as input to Phenix.sculptor (71) to generate the input model for molecular replacement. Phenix (72) was used with the Phaser simple component interface to run a molecular replacement searching for two molecules in the asymmetric unit as indicated by the Matthews coefficient (\(V_m = 2.18\) and solvent content of 43.6% with two molecules in the asymmetric unit). A final TFZ value of 30.2 indicated a clear solution, and after a round of automated model building with AutoBuild (73), a model with \(R_{work}/R_{free}\) of 23.86/26.14 and 884 residues was produced. Model building was completed by several rounds of rebuilding in Coot (74) with refinement using Phenix.refine (75) at 1.3 Å resolution using riding hydrogens and six TLS groups per monomer. Ca\(^{2+}\) was

---

*Structure and function of polyM-specific alginate lyase*
Structure and function of polyM-specific alginate lyase

added in the known binding site. An acetate from the crystallization conditions could be modeled in the active site. The structure was deposited to the Protein Data Bank with PDB code 6QPS.

Glide docking of tetramannuronic acid (DP4M)

DP4M was built in Accelrys Discovery Studio. BcelPL6 and DP4M were prepared using Protein Preparation Wizard and LigPrep programs, respectively, within the Schrödinger suite 2016-1 (Small-Molecule Drug Discovery Suite 2016-1, Schrödinger, LLC, New York). Protein and ligand preparation were performed at pH 7.3 (PROppka (47) and Epik (76, 77)) with default settings for the remaining parameters.

Grid generation was carried out using default parameters. The docking region was centered at the geometric center determined by the positions of Ca2+, Arg-216, Lys-249, and Arg-270, and the threshold of ligand size was set to 25 Å, which is ~7 Å longer than the maximum length of DP4M. Docking experiments were performed by Glide (78) using default settings. The first experiments were conducted using Glide SP (78), and the structure with the best glide SP score was used in a Glide XP (78) run. In allenergy calculations the OPLS3 force field (79) was applied.

Author contributions—E. G. P. S. and B. S. conceptualization; E. G. P. S. and F. F. data curation; E. G. P. S., C. D. A., F. F., J. H., D. T., and G. H. P. formal analysis; E. G. P. S. and B. S. supervision; E. G. P. S., C. D. A., F. F., J. H., G. H. P., and D. H. W. validation; E. G. P. S., C. D. A., F. F., J. H., G. H. P., and D. H. W. visualization; E. G. P. S. and F. F. writing—original draft; E. G. P. S. and B. S. project administration; E. G. P. S., C. D. A., F. F., D. T., F. L. A., D. H. W., and B. S. writing—review and editing; A. S., B. E. C., F. L. A., D. H. W., and B. S. resources; D. T. and G. H. P. methodology; E. G. P. S. and B. S. writing—review and editing; A. S., B. E. C., F. L. A., D. H. W., and B. S. funding acquisition.

Acknowledgments—Karina Jansen, Marzanna Due, and Julia Tanasi are gratefully acknowledged for technical assistance. The NanoDSC is granted by the Carlsberg Foundation, Novo Nordisk Foundation Grant NNF10CC10165. The Norwegian Council of Norway through Grant 294946. Microencapsulation of alginate lyase genes from the marine bacterium Vibrio sp. O2. V. Anraku, M. Nakagawa, S., and Ojima, T. (2016) Discovery of a novel alginate lyase from Nitratiruptor sp. SB155-2 thriving at deep-sea hydrothermal vents and identification of the residues responsible for its heat stability. J. Biol. Chem. 291, 15551–15563 CrossRef Medline

References

1. Haug, A., Larsen, B., and Smidsrod, O. (1967) Studies on sequence of uronic acid residues in alginic acid. Acta Chem. Scand. 21, 691–704 CrossRef
2. Aarstad, O. A., Tondervik, A., Sletta, H., and Skjåk-Bræk, G. (2012) Alginate sequencing: an analysis of block distribution in alginites using specific alginate degrading enzymes. Bioinorganicmolecules 13, 106–116 CrossRef Medline
3. Lombard, V., Golaconda Ramulu, H., Drula, E., Coutinho, P. M., and Henrissat, B. (2014) The carbohydrate-active enzymes database (CAZy) in 2013. Nucleic Acids Res. 42, D490–D495 CrossRef Medline
4. Yoo, M., Wu, J., Li, B., Xiao, H., McClements, D. J., and Li, L. (2017) Microencapsulation of Lactobacillus salivarious subcl strain L010 for enhanced storage ability and targeted delivery to gut microbiota. Food Hydrocoll. 72, 228–236 CrossRef
5. Xu, X., Bi, D., and Wan, M. (2016) Characterization and immunological evaluation of low-molecular-weight alginate derivatives. Curr. Top. Med. Chem. 16, 874–887 CrossRef Medline
6. Oudson, S. T., Váquez-Roque, M. I., Camilleri, M., Papathanasopoulos, A., Clark, M. M., Wodrich, L., Lemple, M., McKinzie, S., Ryks, M., Burton, D., and Zinsmeister, A. R. (2010) Effect of alginate on satiation, appetite, gastric function, and selected gut satiety hormones in overweight and obesity. Obesity 18, 1579–1584 CrossRef Medline
7. Okolie, C. L., Subin, S. R., Udenigwe, C. C., Aryee, A. N. A., and Mason, B. (2017) Prospects of brown seaweed polysaccharides (BSP) as prebiotics and potential immunomodulators. J. Food Biochem. 41, 1–12 CrossRef
8. Utuva, V., Maturana, N., Acevedo, F., Peña, C., and Dáez-Barrera, A. (2017) Bacterial alginate production: an overview of its biosynthesis and potential industrial production. World J. Microbiol. Biotechnol. 33, 198 CrossRef Medline
9. Akiyama, H., Endo, T., Nakakita, R., Murata, K., Yonemoto, Y., and Okayama, K. (1992) Effect of depolymerized alginites on the growth of bifidobacteria. Biosci. Biotechnol. Biochem. 56, 355–356 CrossRef Medline
10. An, C., Kuda, T., Yazaki, T., Takahashi, H., and Kimura, B. (2013) Flex pyrosequencing analysis of the effects of the brown-algal fermentable polysaccharides alginate and laminarin on rat cecal microbiota. Appl. Environ. Microbiol. 79, 860–866 CrossRef Medline
11. Bai, S., Chen, H., Zhu, L., Liu, W., Yu, H. D., Wang, X., and Yin, Y. (2017) Comparative study on the in vitro effects of Pseudomonas aeruginosa and seaweed algae on human gut microbiota. PLoS ONE 12, e0171576 CrossRef Medline
12. Li, M., Li, G., Shang, Q., Chen, X., Liu, W., Pi, X., Zhu, L., Yin, Y., Yu, G., and Wang, X. (2016) In vitro fermentation of alginate and its derivatives by human gut microbiota. Anaerobe 39, 19–25 CrossRef Medline
13. Li, M., Shang, Q., Li, G., Wang, X., and Yu, G. (2017) Degradation of marine algae-derived carbohydrates by bacteroidetes isolated from human gut microbiota. Mar. Drugs 15, E92 CrossRef Medline
14. Mathieu, S., Touvrey-Loiodice, M., Poulet, L., Drouillard, S., Vincentelli, R., Henrissat, B., Skjåk-Bræk, G., and Helbert, W. (2018) Ancient acquisition of “alginate utilization loci” by human gut microbiota. Sci. Rep. 8, 8075 CrossRef Medline
15. Kabisch, A., Otto, A., König, S., Becher, D., Albrecht, D., Schüler, M., Teeling, H., Amann, R. I., and Schweber, T. (2014) Functional characterization of polysaccharide utilization loci in the marine Bacteroidetes’ Gramella forsetii KT0803. ISME J. 8, 1492–1502 CrossRef Medline
16. Inoue, A., Anraku, M., Nakagawa, S., and Ojima, T. (2016) Discovery of a novel alginate lyase from Nitratiruptor sp. SB155-2 thriving at deep-sea hydrothermal vents and identification of the residues responsible for its heat stability. J. Biol. Chem. 291, 15551–15563 CrossRef Medline
17. Kawamoto, H., Horibe, A., Miki, Y., Kimura, T., Tanaka, K., Nakagawa, T., Kawamukai, M., and Matsuda, H. (2006) Cloning and sequencing analysis of alginate lyase genes from the marine bacterium Vibrio sp. O2. Mar. Biotechnol. 8, 481–490 CrossRef Medline
18. Helbert, W., Poulet, L., Drouillard, S., Mathieu, S., Loiodice, M., Couturier, M., Lombard, V., Terrapon, N., Turchetto, J., Vincentelli, R., and Henris- sat, B. (2019) Discovery of novel carbohydrate-active enzymes through the rational exploration of the protein sequences space. Proc. Natl. Acad. Sci. U.S.A. 116, 6063–6068 CrossRef Medline
19. Lombard, V., Bernard, T., Rancurel, C., Brumer, H., Coutinho, P. M., and Henrissat, B. (2010) A hierarchical classification of polysaccharide lyases for glycogenomics. Biochem. J. 432, 437–444 CrossRef Medline
20. Mathieu, S., Henrissat, B., Labre, F., Skjåk-Bræk, G., and Helbert, W. (2016) Functional exploration of the polysaccharide lyase family PL6. PLoS ONE 11, e0159415 CrossRef Medline
21. Garron, M. L., and Cygler, M. (2010) Structural and mechanistic classification of uronic acid-containing polysaccharide lyases. Glycobiology 20, 1547–1573 CrossRef Medline
22. Xu, F., Wang, P., Zhang, Y. Z., and Chen, X. L. (2018) Diversity of three-dimensional structures and catalytic mechanisms of alginate lyases. Appl. Environ. Microbiol. 84, e02040-17 CrossRef Medline
23. Lee, S. I., Choi, S. H., Lee, Y. E., and Kim, H. S. (2012) Molecular cloning, purification, and characterization of a novel polyM-specific alginate lyase responsible for alginate MG block degradation in Stenotrophomas
24. Li, S., Wang, L., Han, F., Gong, Q., and Yu, W. (2016) Cloning and characterization of the first polysaccharide lyase family 6 oligoalginase lyase from marine Shewanella sp. KZ7. J. Biochem. 159, 77–86 CrossRef Medline

25. Garron, M. L., and Cygler, M. (2014) Uronic polysaccharide degrading enzymes. Curr. Opin. Struct. Biol. 28, 87–95 CrossRef Medline

26. Huang, W., Matte, A., Li, Y., Kim, R. J., Su, H., and Cygler, M. (1999) Crystal structure of chondroitinase B from Flavobacterium heparinum and its complex with a disaccharide product at 1.7 Å resolution. J. Mol. Biol. 294, 1257–1269 CrossRef Medline

27. Xu, F., Dong, F., Wang, P., Cao, H. Y., Li, C. Y., Li, P. Y., Pang, X. H., Zhang, Y. Z., and Chen, X. L. (2017) Novel molecular insights into the catalytic mechanism of marine bacterial alginate lyase AlyGC from polysaccharide lyase Family 6. J. Biol. Chem. 292, 4457–4468 CrossRef Medline

28. Lyu, Q., Zhang, K., Shi, Y., Li, W., Diao, X., and Liu, W. (2019) Structural insights into a novel Ca2+-independent PL-6 alginate lyase from Vibrio OUt02 identify the possible substrates responsible for product distribution. Biochim. Biophys. Acta 1863, 1167–1176 CrossRef Medline

29. Michel, G., Pojaszek, K., Li, Y., Sulea, T., Linhardt, R. J., Raman, R., Praha-kar, V., Saisekharan, R., and Cygler, M. (2004) The structure of chondroitin B lyase complexed with glycosaminoglycan oligosaccharides unravels a calcium-dependent catalytic machinery. J. Biol. Chem. 279, 32882–32896 CrossRef Medline

30. Gacesa, P. (1987) Alginate-modifying enzymes. A proposed unified mechanism of action for the lyases and epimerases. FEBS Lett. 212, 199–202 CrossRef

31. Koch, H., Dürwald, A., Schwerdt, T., Noriega-Ortega, B., Vidal-Melgosa, S., Hehemann, J. H., Dittmar, T., Freese, H. M., Becker, D., Simon, M., and Wietz, M. (2019) Biphasic cellular adaptations and ecological implications of Alteromonas macleodii degrading a mixture of algal polysaccharides. ISME J. 13, 92–103 CrossRef Medline

32. Terrapon, N., Lombard, V., Drula, E., Lapèbie, P., Al-Masaoudi, S., Gilbert, H. J., and Henrisat, B. (2018) PULDB: the expanded database of polysaccharide utilization loci. Nucleic Acids Res. 46, D677–D683 CrossRef Medline

33. Krissinel, E., and Henrick, K. (2007) Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774–797 CrossRef Medline

34. Jenkins, J., and Pickersgill, R. (2001) The architecture of parallel β-helices and related folds. Prog. Biophys. Mol. Biol. 77, 111–175 CrossRef Medline

35. Jenkins, J., Mayans, O., and Pickersgill, R. (1998) Structure and evolution of parallel β-helix proteins. J. Struct. Biol. 122, 236–246 CrossRef Medline

36. Bryan, A. W., Jr., Starner-Kreinbrink, J. L., Hosur, S. C., Clark, P. L., and Berger, B. (2011) Structure-based prediction reveals capping motifs that inhibit β-helix aggregation. Proc. Natl. Acad. Sci. U.S.A. 108, 11099–11104 CrossRef Medline

37. Maki, H., Morii, A., Fujiyama, K., Kinoshita, S., and Yoshihisa, T. (1993) Cloning, sequence-analysis and expression in Escherichia coli of a gene encoding an alginate lyase from Pseudomonas sp. OS-ALG-9. J. Gen. Microbiol. 139, 987–993 CrossRef Medline

38. Rahman, M. M., Wang, L., Inoue, A., and Ojima, T. (2012) CDNA cloning and bacterial expression of a PL14 alginate lyase from a herbivorous marine snail Littorina breviscula. Carbohydr. Res. 360, 69–77 CrossRef Medline

39. Park, D., Jagtap, S., and Nair, S. K. (2014) Structure of a PL17 family alginate lyase demonstrates functional similarities among exotox epo-lymerases. J. Biol. Chem. 289, 8645–8655 CrossRef Medline

40. Ochiai, A., Yamasaki, M., Mikami, B., Hashimoto, W., and Murata, K. (2010) Crystal structure of exotoxin alginate lyase Atu3025 from Agrobacterium tumefaciens. J. Biol. Chem. 285, 24519–24528 CrossRef Medline

41. Mikami, B., Ban, M., Suzuki, S., Yoon, H. J., Miyake, O., Yamasaki, M., Ogura, K., Maruyama, Y., Hashimoto, W., and Murata, K. (2012) Induced-fit motion of a lid loop involved in catalysis in alginate lyase Al-III. Acta Crystallogr. D. Biol. Crystallogr. 68, 1207–1216 CrossRef Medline

42. Dong, S., Wei, T. D., Chen, X. L., Li, C. Y., Wang, P., Xie, B. B., Qin, Q. L., Zhang, X. Y., Pang, X. H., Zhou, B. C., and Zhang, Y. Z. (2014) Molecular insight into the role of the N-terminal extension in the maturation, sub-
Structure and function of polyM-specific alginate lyase

61. Park, H. H., Kam, N., Lee, E. Y., and Kim, H. S. (2012) Cloning and characterization of a novel oligoalginate lyase from a newly isolated bacterium *Sphingomonas* sp. MJ-3. *Mar. Biotechnol.* **14**, 189–202 CrossRef Medline

62. Iwamoto, Y., Araki, R., Iriyama, K., Oda, T., Fukuda, H., Hayashida, S., and Muramatsu, T. (2001) Purification and characterization of bifunctional alginate lyase from *Alteromonas* sp. strain No. 272 and its action on saturated oligomeric substrates. *Biosci. Biotechnol. Biochem.* **65**, 133–142 CrossRef Medline

63. Farrell, E. K., and Tipton, P. A. (2012) Functional characterization of AlgL, an alginate lyase from *Pseudomonas aeruginosa*. *Biochemistry* **51**, 10259–10266 CrossRef Medline

64. Michaelis, L., Menten, M. L., Johnson, K. A., and Goody, R. S. (2011) The original Michaelis constant: translation of the 1913 Michaelis-Menten paper. *Biochemistry* **50**, 8264–8269 CrossRef Medline

65. Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Kri ssinel, E., Leslie, A. G., McCoy, A., McNicholas, S. J., Murshudov, G. N., Pannu, N. S., Potterson, E. A., Powell, H. R., et al. (2011) Overview of the CCP4 suite and current developments. *Acta Crystallogr. D Biol. Crystallogr.* **67**, 235–242 CrossRef Medline

66. Evans, P. R., and Murshudov, G. N. (2013) How good are my data and what is the resolution? *Acta Crystallogr. D Biol. Crystallogr.* **69**, 1204–1214 CrossRef Medline

67. Winter, G. (2010) Xia2: an expert system for macromolecular crystallography data reduction. *J. Appl. Crystallogr.* **43**, 186–190 CrossRef

68. Evans, P. (2006) Scaling and assessment of data quality. *Acta Crystallogr. D Biol. Crystallogr.* **62**, 72–82 CrossRef Medline

69. Winter, G., Waterman, D. G., Parkhurst, J. M., Brewster, A. S., Gildea, R. J., Gerstel, M., Fuentes-Montero, L., Vollmar, M., Michels-Clark, T., Young, I. D., Sauter, N., and Evans, G. (2018) DIALS: Implementation and evaluation of a new integration package. *Acta Crystallogr. D Struct. Biol.* **74**, 85–97 CrossRef Medline

70. McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., and Read, R. J. (2007) Phaser crystallographic software. *J. Appl. Crystallogr.* **40**, 658–674 CrossRef Medline

71. Bunkóczi, G., and Read, R. J. (2011) Improvement of molecular-replacement models with Sculptor. *Acta Crystallogr. D Biol. Crystallogr.* **67**, 303–312 CrossRef Medline

72. Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L. W., Kapral, G. J., Grosse-Kunstleve, R. W., McCoy, A. J., Moriarty, N. W., Oeffner, R., Read, R. J., Richardson, D. C., et al. (2010) PHENIX: A comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr. D Biol. Crystallogr.* **66**, 213–221 CrossRef Medline

73. Terwilliger, T. C., Grosse-Kunstleve, R. W., Afonine, P. V., Moriarty, N. W., Zwart, P. H., Hung, L. W., Read, R. J., and Adams, P. D. (2008) Iterative model building, structure refinement and density modification with the PHENIX AutoBuild wizard. *Acta Crystallogr. D Biol. Crystallogr.* **64**, 61–69 CrossRef Medline

74. Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010) Features and development of Coot. *Acta Crystallogr. D Biol. Crystallogr.* **66**, 486–501 CrossRef Medline

75. Afonine, P. V., Grosse-Kunstleve, R. W., Echols, N., Headd, J. J., Moriarty, N. W., Mustyakimov, M., Terwilliger, T. C., Uzhumtsev, A., Zwart, P. H., and Adams, P. D. (2012) Towards automated crystallographic structure refinement with phenix.refine. *Acta Crystallogr. D Biol. Crystallogr.* **68**, 352–367 CrossRef Medline

76. Shelley, J. C., Cholleti, A., Frye, L. L., Greenwood, J. R., Timlin, M. R., and Uchimaya, M. (2007) Epik: a software program for pKa prediction and protonation state generation for drug-like molecules. *J. Comput. Aided Mol. Des.* **21**, 681–691 CrossRef Medline

77. Greenwood, J. R., Calkins, D., Sullivan, A. P., and Shelley, J. C. (2010) Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution. *J. Comput. Aided Mol. Des.* **24**, 591–604 CrossRef Medline

78. Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, I. K., Shaw, D. E., Francis, P., and Shenkin, P. S. (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. method and assessment of docking accuracy. *J. Med. Chem.* **47**, 1739–1749 CrossRef Medline

79. Harder, E., Damm, W., Mappe, J., Wu, C., Reboul, M., Xiang, J. Y., Wang, L., Lupyan, D., Dahlgren, M. K., Knight, J. L., Kaus, J. W., Cerutti, D. S., Kri lov, G., Jorgensen, W. L., Abel, R., and Friesner, R. A. (2016) OPLS3: A force field providing broad coverage of drug-like small molecules and proteins. *J. Chem. Theory Comput.* **12**, 281–296 CrossRef Medline